Skip to main content
SpringerLink
Log in

Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Multikinase inhibitors (MKIs) are targeted cancer therapies designed to inhibit multiple tyrosine kinase pathways responsible for tumor proliferation, growth, and survival. These agents are more able to target cancer cells and possess better safety profiles than conventional chemotherapies. However, MKIs can produce significant cutaneous adverse events, hand–foot skin reaction (HFSR) being the most clinically significant. Although not life threatening, HFSR can lead to MKI dose modification, interruption, or termination, potentially limiting the anti-tumor effect. This article summarizes the current knowledge concerning the epidemiology, clinical presentation, pathogenesis, histopathology, prognostic implication, and current evidence-based prophylactic and reactive treatment options for MKI-induced HFSR. Its high incidence and significant impact on the quality of life emphasizes the great need to understand the pathogenesis and improve management of this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Peuvrel L, Dreno B. Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol. 2014;15(5):425–44.

    Article  PubMed  Google Scholar 

  2. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist. 2011;16(11):1508–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, et al. Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death. Cancer Res. 2016;76(1):117–26.

    Article  CAS  PubMed  Google Scholar 

  4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. US Department of Health and Human Services. National Institute of Health. National Cancer Institute. May 28, 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-0614_QuickReference_5x7.pdf. Accessed 1 Feb 2016

  5. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971–9.

    Article  CAS  PubMed  Google Scholar 

  6. Stjepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics. 2014;8:129–39.

    PubMed  PubMed Central  Google Scholar 

  7. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–55.

    Article  CAS  PubMed  Google Scholar 

  8. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001–11.

    Article  CAS  PubMed  Google Scholar 

  9. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454(7204):656–60.

    Article  CAS  PubMed  Google Scholar 

  10. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J. 2004;18(2):338–40.

    CAS  PubMed  Google Scholar 

  11. McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26(10):2017–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491–500.

    Article  CAS  PubMed  Google Scholar 

  13. Garuti L, Roberti M, Bottegoni G. Multi-kinase inhibitors. Curr Med Chem. 2015;22(6):695–712.

    Article  CAS  PubMed  Google Scholar 

  14. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886–92.

    Article  CAS  PubMed  Google Scholar 

  15. Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2012;30(4):1773–81.

    Article  CAS  PubMed  Google Scholar 

  16. Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol. 2016;41(1):8–15.

    Article  CAS  PubMed  Google Scholar 

  17. Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs. 2013;31(4):1078–86.

    Article  CAS  PubMed  Google Scholar 

  18. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176–86.

    Article  CAS  PubMed  Google Scholar 

  19. Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol. 2009;27(25):4169–76.

    Article  CAS  PubMed  Google Scholar 

  20. Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31(3):787–97.

    Article  CAS  PubMed  Google Scholar 

  21. Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148(12):1418–20.

    Article  PubMed  Google Scholar 

  22. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–71.

    Article  CAS  PubMed  Google Scholar 

  23. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2013;370(18):1769–70.

    Article  Google Scholar 

  24. Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, et al. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs. 2013;31(4):1008–15.

    Article  CAS  PubMed  Google Scholar 

  25. Vermersch P, Benrabah R, Schmidt N, Zephir H, Clavelou P, Vongsouthi C, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012;12:36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kontzias A, Laurence A, Gadina M, O’Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep. 2012;4:5.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 1974;148(2):90–2.

    Article  CAS  PubMed  Google Scholar 

  28. Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97(1):61–2.

    Article  CAS  PubMed  Google Scholar 

  29. Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–94.

    Article  PubMed  Google Scholar 

  30. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Ann Oncol. 2007;18(7):1159–64.

    Article  CAS  PubMed  Google Scholar 

  31. Sehouli J, Oskay-Ozcelik G, Kuhne J, Stengel D, Hindenburg HJ, Klare P, et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol. 2006;17(6):957–61.

    Article  CAS  PubMed  Google Scholar 

  32. Strauss HG, Hemsen A, Karbe I, Lautenschlager C, Persing M, Thomssen C. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs. 2008;19(5):541–5.

    Article  CAS  PubMed  Google Scholar 

  33. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis. Curr Med Res Opin. 2015;31(5):975–86.

    Article  CAS  PubMed  Google Scholar 

  34. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148(5):628–33.

    Article  CAS  PubMed  Google Scholar 

  35. Lilly E, Burke M, Kluger H, Choi J. Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib. JAMA Dermatol. 2015;151(1):102–3.

    Article  PubMed  Google Scholar 

  36. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7.

    Article  CAS  PubMed  Google Scholar 

  37. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy—classification and management. J Dtsch Dermatol Ges. 2010;8(9):652–61.

    PubMed  Google Scholar 

  39. Massey PR, Okman JS, Wilkerson J, Cowen EW. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer. 2015;23(6):1827–35.

    Article  PubMed  Google Scholar 

  40. Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2013;119(1):136–42.

    Article  CAS  PubMed  Google Scholar 

  41. Gomez-Martin C, Sanchez A, Irigoyen A, Llorente B, Perez B, Serrano R, et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012;14(9):689–97.

    Article  CAS  PubMed  Google Scholar 

  42. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12(3):131–41.

    Article  CAS  PubMed  Google Scholar 

  43. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51.

    Article  CAS  PubMed  Google Scholar 

  44. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  45. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  46. Bos WE, Nijsten TE, de Jonge MJ, Hamberg AP. Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome. Arch Dermatol. 2012;148(4):546–7.

    Article  CAS  PubMed  Google Scholar 

  47. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25–35.

    Article  CAS  PubMed  Google Scholar 

  48. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(27):4462–8.

    Article  CAS  PubMed  Google Scholar 

  49. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12(4):426–37.

    Article  CAS  PubMed  Google Scholar 

  50. Tsuchiya N, Narita S, Inoue T, Hasunuma N, Numakura K, Horikawa Y, et al. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs. 2013;24(3):310–4.

    Article  CAS  PubMed  Google Scholar 

  51. Hilger RA, Kredtke S, Scheulen ME, Seeber S, Strumberg D. Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther. 2004;42(11):648–9.

    Article  CAS  PubMed  Google Scholar 

  52. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007;27(8):1125–44.

    Article  CAS  PubMed  Google Scholar 

  53. Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23(12):1233–8.

    Article  CAS  PubMed  Google Scholar 

  54. Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol. 2012;23(8):2103–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Yang CH, Chuang CK, Hsieh JJ, Chang JW. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf. 2010;9(3):459–70.

    Article  CAS  PubMed  Google Scholar 

  56. Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210–1.

    Article  CAS  PubMed  Google Scholar 

  57. Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy. 2010;30(1):52–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, et al. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. J Anal Toxicol. 2010;35(8):558–65.

    Article  Google Scholar 

  59. Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, et al. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. Eur J Clin Pharmacol. 2013;69(12):2065–72.

    Article  CAS  PubMed  Google Scholar 

  60. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955–61.

    Article  CAS  PubMed  Google Scholar 

  61. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol. 2005;74(2):121–3.

    Article  CAS  PubMed  Google Scholar 

  62. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994;42(11):1417–25.

    Article  CAS  PubMed  Google Scholar 

  63. Ponten F, Ren Z, Nister M, Westermark B, Ponten J. Epithelial-stromal interactions in basal cell cancer: the PDGF system. J Invest Dermatol. 1994;102(3):304–9.

    Article  CAS  PubMed  Google Scholar 

  64. Judith R, Nithya M, Rose C, Mandal AB. Application of a PDGF-containing novel gel for cutaneous wound healing. Life Sci. 2010;87(1–2):1–8.

    Article  CAS  PubMed  Google Scholar 

  65. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.

    Article  PubMed  Google Scholar 

  66. Hoesly FJ, Baker SG, Gunawardane ND, Cotliar JA. Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. Arch Dermatol. 2011;147(12):1418–23.

    Article  CAS  PubMed  Google Scholar 

  67. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592–6.

    Article  CAS  PubMed  Google Scholar 

  68. Chanprapaph K, Pongcharoen P, Vachiramon V. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases. Indian J Dermatol Venereol Leprol. 2015;81(5):547.

    PubMed  Google Scholar 

  69. Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE. 2013;8(1):e55128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Kucharz J, Dumnicka P, Kuzniewski M, Kusnierz-Cabala B, Herman RM, Krzemieniecki K. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study. Tumori. 2015;101(5):555–9.

    Article  PubMed  Google Scholar 

  71. Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol. 2012;23(12):3137–43.

    Article  CAS  PubMed  Google Scholar 

  72. Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, et al. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol. 2013;43(10):1023–9.

    Article  PubMed  Google Scholar 

  73. Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16(10):1469–78.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33.

    Article  PubMed  Google Scholar 

  75. Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol. 2012;11(11):e61–5.

    PubMed  Google Scholar 

  76. Anderson RT, Keating KN, Doll HA, Camacho F. The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology. Oncologist. 2015;20(7):831–8.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Lai JS, Beaumont JL, Diaz J, Khan S, Cella D. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer. 2016;122(2):287–95.

    Article  CAS  PubMed  Google Scholar 

  78. Mikoshiba N, Yamamoto-Mitani N, Sato K, Asaoka Y, Ohki T, Ohata M, et al. Validation of the Japanese version of HFS-14, a disease-specific quality of life scale for patients suffering from hand-foot syndrome. Support Care Cancer. 2015;23(9):2739–45.

    Article  PubMed  Google Scholar 

  79. De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014;22(3):837–46.

    Article  PubMed  Google Scholar 

  80. Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, et al. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: north Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010;28(35):5182–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Ruhstaller T, Ribi K, Sun H, et al. Prevention of palmoplantar erythrodysesthesia(PPE) with antiperspirant in breast cancer patients treated with pegalated liposomal doxorubicin (PLD),a placebo-controlled, double blinded, phase III trial (SAKK 92/08). J Clin Oncol 2012;30(suppl;abstr 9059).

  82. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008;108(2):332–5.

    Article  CAS  PubMed  Google Scholar 

  83. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol. 1999;44(4):303–6.

    Article  CAS  PubMed  Google Scholar 

  84. Kluschke F, Martschick A, Darvin ME, et al. Application of an ointment with high radical protection factor as a prevention strategy against PPE. J Clin Oncol 2012;30(suppl; abstr 5064).

  85. Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, Hardy R, et al. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer. 2012;107(4):585–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824–9.

    Article  CAS  PubMed  Google Scholar 

  87. von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 2010;116(20):4735–43.

    Article  Google Scholar 

  88. Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, et al. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol. 2008;62(4):717–25.

    Article  CAS  PubMed  Google Scholar 

  89. Kohne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008;19(5):920–6.

    Article  PubMed  Google Scholar 

  90. Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011;137(6):953–7.

    Article  CAS  PubMed  Google Scholar 

  91. Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23(5):1348–53.

    Article  CAS  PubMed  Google Scholar 

  92. Kawaguchi K, Ishiguro H, Morita S, Nakamura S, Ohno S, Masuda N, et al. Correlation between docetaxel-induced skin toxicity and the use of steroids and H(2) blockers: a multi-institution survey. Breast Cancer Res Treat. 2011;130(2):627–34.

    Article  CAS  PubMed  Google Scholar 

  93. Yamamoto D, Yamamoto C, Iwase S, Kuroda Y, Odagiri H, Nagumo Y. Efficacy of vitamin E treatment for hand-foot syndrome in patients receiving capecitabine. Breast Care (Basel). 2010;5(6):415–6.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Kanis M, Kesterson JP, Lele S. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia. Eur J Gynaecol Oncol. 2009;30(4):387–8.

    CAS  PubMed  Google Scholar 

  95. Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585–93.

    PubMed  Google Scholar 

  96. Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(8):894–900.

    Article  CAS  PubMed  Google Scholar 

  97. Bozkurt DB, Kara B, Oguz KI, Demiryurek H, Aksungur E. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study. J Buon. 2011;16(4):759–64.

    Google Scholar 

  98. Li JR, Yang CR, Cheng CL, Ho HC, Chiu KY, Su CK, et al. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Support Care Cancer. 2013;21(3):907–11.

    Article  PubMed  Google Scholar 

  99. Shinohara N, Nonomura N, Eto M, Kimura G, Minami H, Tokunaga S, et al. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol. 2013;25(2):472–6.

    Article  PubMed  Google Scholar 

  100. Zhao C, Chen J, Yu B, Wu X, Dai C, Zhou C, et al. Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome. J Tradit Chin Med. 2014;34(1):10–4.

    Article  CAS  PubMed  Google Scholar 

  101. Cuesta L, Betlloch I, Toledo F, Latorre N, Monteagudo A. Severe sorafenib-induced hand-foot skin reaction. Dermatol Online J. 2011;17(5):14.

    CAS  PubMed  Google Scholar 

  102. Hutten M, Lassay L, Sachs B, Deutz P, Mertens R, Baron JM, et al. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma. Pediatr Dermatol. 2009;26(3):349–50.

    Article  PubMed  Google Scholar 

  103. Hung CT, Chiang CP, Wu BY. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy. J Dermatol. 2012;39(12):1076–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand

    Kumutnart Chanprapaph, Suthinee Rutnin & Vasanop Vachiramon

Authors
  1. Kumutnart Chanprapaph
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suthinee Rutnin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vasanop Vachiramon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kumutnart Chanprapaph.

Ethics declarations

Funding

No funding was received in the preparation of this review.

Conflict of interest

Kumutnart Chanprapaph, Suthinee Rutnin, and Vasanop Vachiramon have no conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chanprapaph, K., Rutnin, S. & Vachiramon, V. Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol 17, 387–402 (2016). https://doi.org/10.1007/s40257-016-0197-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-016-0197-1

Keywords

Search

Navigation